Alder BioPharmaceuticals Inc. (NASDAQ:ALDR) shares shot up 4.3% during mid-day trading on Friday . The company traded as high as $26.99 and last traded at $26.67, with a volume of 499,387 shares changing hands. The stock had previously closed at $25.56.

A number of brokerages have recently issued reports on ALDR. Zacks Investment Research downgraded Alder BioPharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, May 3rd. Brean Capital reiterated a “buy” rating on shares of Alder BioPharmaceuticals in a report on Saturday, April 30th. Wells Fargo & Co. began coverage on Alder BioPharmaceuticals in a report on Thursday, April 21st. They issued an “outperform” rating on the stock. Leerink Swann reiterated an “outperform” rating on shares of Alder BioPharmaceuticals in a report on Tuesday, March 29th. Finally, Jefferies Group reiterated a “buy” rating on shares of Alder BioPharmaceuticals in a report on Thursday, June 30th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $52.00.

The firm’s market cap is $1.29 billion. The firm has a 50-day moving average of $27.34 and a 200 day moving average of $25.41.

Alder BioPharmaceuticals (NASDAQ:ALDR) last announced its quarterly earnings data on Thursday, April 28th. The biopharmaceutical company reported ($0.76) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.72) by $0.04. During the same quarter in the prior year, the firm earned ($0.40) earnings per share. Analysts predict that Alder BioPharmaceuticals Inc. will post ($3.25) earnings per share for the current year.

In other Alder BioPharmaceuticals news, VP Jeffrey T. L. Smith sold 16,090 shares of Alder BioPharmaceuticals stock in a transaction that occurred on Friday, June 3rd. The stock was sold at an average price of $30.20, for a total value of $485,918.00. Following the sale, the vice president now owns 16,090 shares of the company’s stock, valued at approximately $485,918. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Mark James Litton sold 6,000 shares of Alder BioPharmaceuticals stock in a transaction that occurred on Monday, June 13th. The shares were sold at an average price of $28.94, for a total value of $173,640.00. Following the completion of the sale, the insider now directly owns 74,567 shares in the company, valued at approximately $2,157,968.98. The disclosure for this sale can be found here.

A number of large investors have made changes to their positions in the stock. ProShare Advisors LLC raised its stake in shares of Alder BioPharmaceuticals by 8.6% in the fourth quarter. ProShare Advisors LLC now owns 38,476 shares of the biopharmaceutical company’s stock worth $1,271,000 after buying an additional 3,058 shares in the last quarter. Nationwide Fund Advisors raised its stake in shares of Alder BioPharmaceuticals by 103.6% in the fourth quarter. Nationwide Fund Advisors now owns 30,380 shares of the biopharmaceutical company’s stock worth $1,003,000 after buying an additional 15,457 shares in the last quarter. Pyrrho Capital Management LP increased its stake in Alder BioPharmaceuticals by 205.0% in the fourth quarter. Pyrrho Capital Management LP now owns 63,000 shares of the biopharmaceutical company’s stock worth $2,081,000 after buying an additional 42,343 shares during the last quarter. California Public Employees Retirement System increased its stake in Alder BioPharmaceuticals by 834.5% in the fourth quarter. California Public Employees Retirement System now owns 81,300 shares of the biopharmaceutical company’s stock worth $2,685,000 after buying an additional 72,600 shares during the last quarter. Finally, Wells Fargo & Company MN increased its stake in Alder BioPharmaceuticals by 290.6% in the fourth quarter. Wells Fargo & Company MN now owns 269,774 shares of the biopharmaceutical company’s stock worth $8,911,000 after buying an additional 200,707 shares during the last quarter.

Alder Biopharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and focuses to commercialize therapeutic antibodies with the potential to transform current treatment paradigms. The Company has developed an antibody platform designed to select antibodies that have the potential to maximize efficacy, as well as speed of onset and durability of therapeutic response.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.